Moreover, Peng et al. [99] reported that enolase 1 (ENO1) serves as a key biomarker for CML response to tyrosine kinase inhibitors (TKIs), ENO1 inhibiton could augment TKIs sensitivity and promote the ferroptosis susceptibility in TKIs-resistant cells by ultimately inducing GPX4 autophagic degradation through AMPK/mTOR. Here, ENO1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.